CSF2 and neoplasm: A recent manuscript reports that a similar recombinant NDV (rNDVhuGM-CSF (MEDI5395 from Astra Zeneca)) combined broad oncolytic activity with the ability to modulate genes related to immune functionality in human tumor cells [129].